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VT and Sudden Death in HCM Patients
The suggestion by McKenna and Camml in a recent editorial comment on our study2 that ventricular tachycardia (VT) on Holter is not causally related to sudden cardiac death in hypertrophic cardiomyopathy (HCM) patients but may be simply a marker of the patients at risk for dying may be valid. However, because the incidence of sudden cardiac death in patients with HCM is fourfold higher in patients with VT during Holter monitoring, a more plausible hypothesis is that VT is indeed an important triggering mechanism for lethal and sustained arrhythmias. The fact, however, that the large majority of patients with VT do not die suddenly raises the intriguing possibility that these lethal arrhythmias will be triggered only in those patients with an arrhythmogenic ventricular substrate. In addition to nonsustained VT, there are undoubtedly other initiating or aggravating mechanisms, and McKenna and Camm speculate on some of these.
The concept that sudden cardiac death in patients with HCM requires both a triggering mechanism and an arrhythmogenic substrate provides the pathophysiologic context by which the results of our study can best be understood. Thus, the primary role of electrophysiologic studies is to identify those patients who have the arrhythmogenic myocardial substrate. In this regard, two findings are worth emphasizing. First, a history of sudden cardiac arrest or syncope was a very strong independent predictor (p<0.0001) of inducibility of sustained VT; VT was induced in 17 of 22 (77%) of sudden cardiac arrest survivors compared with only six of 34 (18%) asymptomatic patients. The fact that 80% of the asymptomatic patients (who had a low prevalence of inducible VT) had VT on Holter further leads us to the view that without the necessary arrhythmogenic substrate, nonsustained VT is unlikely to trigger ventricular arrhythmias that result in sudden cardiac arrest or syncope. Second, contrary to McKenna's suggestion, the stimulation protocol was identical in all patients and was no more aggressive than that used to evaluate ventricular arrhythmias in other cardiac disease states. Importantly, in the symptomatic patients, sustained VT was induced with significantly (p<0.007) greater ease compared with the stimulation protocol that failed to induce VT in the asymptomatic patients. Although we agree that brief episodes of induced nonsustained VT may be nonspecific, these were not the arrhythmias that were considered to be significant in our study. Induced arrhythmia was sufficiently sustained to result in loss of consciousness in 64 of 66 patients.
Also, electrophysiologic studies can identify other potential mechanisms for cardiac arrest or syncope in patients with HCM, a finding not commented on by McKenna. All of our sudden cardiac arrest survivors in whom sustained VT was not induced had other potential mechanisms for sudden cardiac death identified at combined hemodynamic-electrophysiologic studies: 1) accessory pathways and atrial arrhythmias, 2) sinoatrial disease, 3) heart block, 4) myocardial ischemia, or 5) severe left ventricular outflow tract obstruction. Thus, we found that in patients with sudden cardiac arrest or syncope there is a high likelihood of identifying one of these mechanisms that could cause a fatal event while such mechanisms are uncommonly identified in asymptomatic patients (including those patients with VT on Holter). These results suggest that electrophysiologic studies, combined with clinical assessment, can identify not only patients at high risk of dying but also the potential mechanisms involved, which can then be treated aggressively. Such studies may also identify the patient who has a low risk of dying over the subsequent years. This latter hypothesis is being tested by us by long-term follow-up studies.
Lameh Fananapazir, MD Senior Investigator and Director of Clinical Electrophysiology Laboratory
Stephen E. Epstein, MD
Digital Nerve Blockade in Raynaud's Disease
In response to Coffman's recent editorial comment' on our study of digital nerve blockade in Raynaud's disease,2 we agree with his conclusion that the "local fault" theory of Lewis has now been substantiated. Additional evidence for this theory comes from our finding that local cooling was necessary to produce vasospastic attacks; only one attack occurred in our pilot study, where local cooling was not used. However, we do not agree with Coffman's view that "we still do not know the nature of this abnormality [in the digital circulation] and are therefore no closer to an understanding of episodic digital vasospasm." We recently demonstrated3 that patients with idiopathic Raynaud's disease had greater digital vasoconstrictive responses to brachial artery infusions of al-and a2-adrenergic agonists than age-and gendermatched control subjects. The patients were classified by the same criteria used in the nerve block study and also received the same maximal vasodilation test. There were no differences between the patients and control subjects in their responses to reflex cooling, indirect heating, or intra-arterial infusions of tyramine. Thus, an increase in a-adrenoceptor sensitivity, density, or both has been demonstrated at the tissue level. These results agree with those of two studies4'5 in which platelet ca2-receptors of patients with idiopathic Raynaud's disease were compared with those of normal persons and patients with Raynaud's phenomenon.
The above studies were conducted in conditions that were approximately thermoneutral and therefore do not explain the mechanism through which cooling triggers vasospastic attacks. However, it has recently been shown that local cooling increases a2-and reduces a,-adrenergic vasoconstriction in human fingers6 and that cold-induced vasoconstriction was abolished by an a2-adrenoceptor antagonist but not by an a,-antagonist.7 These studies were conducted in normal persons, and the involvement
